Nasdaq congratulates Signifier Medical Technologies for treating 10,000 patients with eXciteOSA, a daytime therapy for sleep apnea

BOSTON and LONDON – March 29, 2023 Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that eXciteOSA, the only FDA-authorized daytime therapy for sleep-disordered breathing, has treated over 10,000 patients since the commercial launch in 2021. Nasdaq recognized this milestone by congratulating Signifier Medical on the Nasdaq Tower in the heart of Times Square, New York.

Akhil Tripathi, Signifier’s co-founder and CEO said, “This is a proud moment knowing that our therapy has made a positive impact on the lives of so many patients. It’s been a great team effort among our employees, clinicians, distributors, and most of all, our patients.” Signifier Medical is simplifying the complex standard of care for obstructive sleep apnea with eXciteOSA by tackling a root cause – empowering patients to restore their nighttime breathing naturally – with a novel 20-minute daytime therapy.

Past studies have shown that eXciteOSA is associated with reductions in both objectively measured and bed-partner-reported snoring, along with significant improvements in disease severity, measured by the Epworth Sleepiness Scale, and Pittsburgh Sleep Quality Index.1-3 Clinical trial participants experienced a significant reduction in their AHI overall.3

“eXciteOSA is a new and novel daytime treatment for sleep apnea. Burden of use is as low as 20 minutes. Evidence is mounting about the positive effects of eXciteOSA in improving disease severity and daytime sleepiness. Patients now have an alternative approach that is easy to use and well accepted,” said Dr. Naresh M. Punjabi, Ph.D. – Chief, Division of Pulmonary, Critical Care, and Sleep Medicine at the University of Miami.

eXciteOSA is a smart wireless device used for 20 minutes per day paired with an intuitive app and a dedicated Sleep Advocate for one-on-one coaching and support. Joel Hanlon, Manager of Patient Experience, said, “We’re thrilled with how well patients are responding to therapy, and we’re here to support them every step of the way throughout their therapy journey.”

The current standard of care for treating OSA, positive airway pressure (PAP), has long been plagued with low adherence and low patient satisfaction. Based on a recent study, eXciteOSA therapy demonstrates real-world adherence of more than 80%, which is exceptional in this space.

Effective treatment of OSA, which leads to better sleep, unlocks the potential for each of us to do more of what we love in life. We have a good reminder of that this month — March – which is Sleep Awareness Month. It’s a good time to learn about sleep health and seek a diagnosis and treatment for sleep-related conditions. Signifier Medical would like to be a part of that — transforming the standard of care for sleep apnea to help the millions of those suffering from the condition.

About Signifier Medical Technologies

Signifier is a pioneer in addressing the root causes of sleep-disordered breathing. The Company is focused on the development and commercialization of innovative and non-invasive solutions to help people breathe normally and naturally all night – without needing to use a wearable medical device or a surgical implant. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies to improve population health, increase the quality of patient’s healthcare experience, and generate healthcare savings. Signifier has offices in London (UK) and Needham (Massachusetts, USA).

About eXciteOSA®

eXciteOSA is a revolutionary daytime therapy for sleep-disordered breathing. Clinically proven to target a common root cause of OSA, eXciteOSA uses neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles, working the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep. Unlike other devices which are used while patients sleep, eXciteOSA is the first commercially available device used while awake.

Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials. Randomized trials are in progress to understand the potential placebo effect (NCT04974515), the impact of therapy relative to usual care without treatment (NCT05183009NCT05252156), and the impact of therapy amongst those with moderate OSA (NCT05252156).

For more information, please visit www.signifiermedical.com or www.exciteosa.com.

Contacts

Media:
Jay Cranston
Signifier Medical Technologies Inc
[email protected]

Investors and Partners:
Ekin Sezgen
Signifier Medical Technologies Inc
[email protected]

References

  1. Baptista PM, Martinez Ruiz de Apodaca P, Carrasco M, Fernandez S, Wong PY, Zhang H, Hassaan A, Kotecha B. Daytime neuromuscular electrical therapy of tongue muscles in improving snoring in individuals with primary snoring and mild obstructive sleep apnea. Journal of Clinical Medicine 2021;10(9):1-11.
  2. Wessolleck E, Bernd E, Dockter S, Lang S, Sama A, Stuck BA. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie 2018;22(2):47-52.
  3. Nokes B, Baptista PM, de Apodaca PMR, Carrasco-Llatas M, Fernandez S, Kotecha B, Wong PY, Zhang H, Hassaan A, Malhotra A. Transoral awake state neuromuscular electrical stimulation therapy for mild obstructive sleep apnea. Sleep Breath 2022;

Signifier® Medical Technologies to host webinar on precision medicine for obstructive sleep apnoea and emerging technologies

Live Webinar: Thursday 25th June 4pm PDT (26th June 9am AEST, 26th June 12am BST)– FREE

sleep apnoea

LONDON, 9th June 2020

Signifier Medical Technologies today announced that it will host a live webinar on Thursday 25th June 4pm PDT (26th June 9am AEST, 26th June 12am BST) to learn about the latest advances in the management of sleep disordered breathing and emerging new technologies in the field of sleep medicine.

It is thought that up to 70m people in the USA, and 6m people in Australia have sleep disordered breathing, therefore, it is important for health care professionals to be able to offer their patients the latest advances in sleep medicine.

The webinar will feature three experts on sleep disordered breathing, Prof. Dr. Peter Cistulli – Clinical Director of the Sleep Medicine Program at Royal North Shore Hospital University of Sydney and Res Med Chair in Sleep Medicine, Prof. Dr. Malhotra – Research Chief in Pulmonary, critical care and sleep medicine at UC San Diego. He is Peter C. Farrell Presidential chair and Professor in Respiratory Medicine at UCSD, and Prof. Dr. Anshul Sama (FRCS), Founder and Chief Medical Officer of Signifier Medical Technologies and Ear, Nose and Throat Surgeon at the University of Nottingham.

The speakers will cover the following topics in this free webinar:

  • Obstructive Sleep Apnoea: need for bespoke management
  • Emerging technologies and future trends in management of OSA
  • Neuromuscular electrical stimulation: the technology and results

The webinar will include a Q&A session with the speakers.

About Signifier Medical Technologies

Signifier Medical Technologies, previously known as Snoozeal®, is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions.

Signifier’s proprietary therapy is the first and only day time genioglossal muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective treatment for its patients. 1, 2

References

  1. A.Sama et al. Daytime Intraoral Neuromuscular stimulation with Snoozeal® for treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes, 2018
  2. E.Wessoleck et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22(Suppl 2): 47–52.

For media enquiries:
[email protected]
+44 (0) 207 096 0586

Take your first steps towards a restful night’s sleep today

Signifier® Medical Technologies and British Academy of Dental Sleep Medicine to Host Webinar on Latest Advances in the Management of Sleep Disordered Breathing

Free CPD-certified webinar to be hosted live on Wednesday, 29 April at 16:00 BST

LONDON, 20 April 2020
– Signifier Medical Technologies today announced that it will host a webinar about the latest advances in the management of sleep disordered breathing and the role of dentistry in sleep medicine on 29 April, 2020 at 16:00 BST in collaboration with the British Academy of Dental Sleep Medicine.

The webinar will feature two experts on sleep disordered breathing: Dr. Aditi Desai, President of the British Society of Dental Sleep Medicine (BSDSM) and President and Co-Founder of the British Academy of Dental Sleep Medicine (BADSM), and Professor Anshul Sama (FRCS), Founder and Chief Medical Officer of Signifier Medical Technologies and Ear, Nose and Throat Surgeon at the University of Nottingham.

Dr. Desai and Prof Sama will cover the following topics in this free CPD-certified webinar:

  • Snoring and Sleep Apnoea: understanding the condition
  • Obstructive Sleep Apnoea and Dentistry: standard of care and the role of the dentist Neuromuscular Electrical Stimulation (NMES) in the management of sleep disordered breathing

“Dentistry plays an increasingly important role in sleep medicine and this webinar will shed light on important developments in this space; NMES could represent additional, valuable treatment optionality,” said Professor Anshul Sama.

The webinar will include a Q&A session with the speakers. Please register HERE.

About Signifier Medical Technologies

Signifier Medical Technologies, previously known as Snoozeal, is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions.

Signifier’s proprietary therapy is the first and only day time genioglossal muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective treatment for its patients. 1, 2

References

  1. A.Sama et al. Daytime Intraoral Neuromuscular stimulation with Snoozeal® for treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes, 2018
  2. E.Wessoleck et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22(Suppl 2): 47–52.

For media enquiries:
[email protected]
+44 (0) 207 096 0586

Take your first steps towards a restful night’s sleep today

Signifier® Medical Technologies Wins iF Design Award 2020 for Design Excellence for eXciteOSA®, the World’s First, Daytime Treatment Device That Tackles the Root Cause of Sleep Apnoea and Snoring

eXciteOSA Device and SmartPhone

February 25, 2020
– London, United Kingdom – Signifier Medical Technologies Limited is delighted to announce that it has won the prestigious iF DESIGN AWARD for Design Excellence, in the “Product” category, for its novel medical device, eXciteOSA® for patients with sleep apnoea and snoring.

The iF DESIGN AWARD is the oldest independent quality design seal in the world and one of the most important design prizes when it comes to excellence in design. This award exemplifies Signifier Medical Technologies’ commitment to making outstanding, patient-centric design an integral component of the user experience, together with eXciteOSA’s® ergonomic styling, connected smart features and ease of use.

Professor Anshul Sama (FRCS), Founder and Chief Medical Officer of Signifier Medical Technologies and Ear, Nose and Throat Surgeon at the University of Nottingham, was keenly aware of the fact that many of his patients were struggling with conventional treatment options for their sleep apnoea and snoring issues. Based on an understanding of this significant unmet need and working with a talented multidisciplinary team, he created the world’s first, daytime treatment device that tackles the root cause of sleep apnoea – eXciteOSA®.

The eXciteOSA® treatment has been clinically proven with rigorous clinical trials conducted by prestigious institutions showing an objective improvement in sleep quality by reducing sleep apnoea and snoring significantly. 1, 2

Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnoea (OSA) globally. There is also a strong, clinically proven link between obstructive sleep apnoea and co-morbidities like diabetes, hypertension and strokes.

Professor Sama commented: “Our team is thrilled to have been awarded such a prestigious honour from iF International Forum Design. eXciteOSA® is a result of a devoted effort by many highly skilled professionals from sleep medicine, maxillofacial surgery, product development, medical engineering, software engineering and regulatory that led to an easy-to-use, effective product that will be readily available to all and workable through a phone app. We are looking forward to bringing eXciteOSA® to market and helping more people improve their quality of sleep with this easy-to-use and effective solution.”

Organized by iF International Forum Design GmbH, the iF Design Award contest started in Germany in 1953. Design submissions are subject to comprehensive evaluation for design, innovativeness, functionality and seven additional categories including product, packaging, communication and professional concepts.

iF Design Award 2020 winners are announced online through the iF Design Award website and iF Design app and winning designs will be presented at the iF Design Exhibition from 2-10 May during Berlin Design Week 2020.

More information about the eXciteOSA iF DESIGN AWARD can be found in the “Design Excellence” section of the iF WORLD DESIGN GUIDE https://ifworlddesignguide.com

For the eXciteOSA® entry go to: https://ifworlddesignguide.com/search?search=snoozeal#/page/entry/285464-snoozeal

Images of the eXciteOSA® device are available upon request to [email protected]

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnoea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnoea and co-morbidities like diabetes, hypertension and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnoea is marked by recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day and decreased intellectual alertness. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnoea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a demand for new forms of treatment.

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialisation of innovative and non-invasive solutions for patients with snoring and sleep-disordered breathing conditions. Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective treatment for its patients. 1, 2

About the iF DESIGN AWARD

The iF DESIGN AWARD has been a globally recognized trademark when it comes to excellence in design for 67 years. The iF brand enjoys an international reputation as a symbol for outstanding design achievement. The iF DESIGN AWARD is one of the most important design prizes in the world. It honours design achievements in all disciplines: product, packaging, communication and service design, architecture and interior architecture as well as professional concepts. All the award-winning entries are presented in the iF WORLD DESIGN GUIDE, published in the iF design app and exhibited at the iF design exhibition in Berlin.

References

  1. 1. A.Sama et al. Daytime Intraoral Neuromuscular stimulation with Snoozeal® for treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes, 2018
  2. 2. E.Wessoleck et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22(Suppl 2): 47–52.

For more information, please contact us at:
[email protected]
+44 (0) 207 096 0586

Take your first steps towards a restful night’s sleep today